WCC has certainly evolved since our early beginnings as a spin-out from MGH.
Over our twenty years, we’ve expanded our service offerings to include blinded independent central reviews (BICRs) of any subjective clinical data while staying focused on our core business: being an imaging CRO that employs imaging expertise, innovative technology and operational excellence to maximize the precision and accuracy of BICRs. As imaging has become more quantitative, we have added biostatistics, a 3D/quantification laboratory and enhanced the capabilities of our digital portal WorldPRO to keep pace with requirement for electronic submissions.
What makes WCC stand out as your imaging trials partner? It is our commitment to operational excellence, the personal accountability of our staff and our ability to leverage medical expertise, particularly in radiological subspecialties through our strategic relationship with MGH. In addition, we have an intense focus on improving the quality of BICR data. This stems from my background, and that of some of the employees of WCC, who in previous positions developed novel medical imaging agents. When you develop a novel imaging agent, you have to consistently train and test readers on how to correctly interpret images. Because the divisions of the FDA that approve medical imaging agents set policy standards for imaging in clinical trials, and consult with all other divisions of the FDA, we have a forward-looking understanding of what is required when using imaging as an important endpoint in a therapeutic trial.
For sponsors looking to further enhance surrogate imaging endpoints by incorporating a more holistic evaluation of patient data, we offer services specifically designed to manage this process. We leverage expert clinicians to provide subjective assessments of clinical data used to determine disease progression in oncology, tumor grading in pathology, lesion characterization in dermatology, and adverse experience assessments in cardiology and neurology.
In September, we introduced an enhanced version of our WorldPRO platform to support complex EAC reviews by integrating the review of radiology, pathology, photography, and clinical data. This integration enables a more efficient review, reducing study timelines and improving data accuracy. We’ve also expanded our service offerings to include specialized support for sponsors conducting MS, melanoma and Alzheimer’s trials.
And to this day, we continue to build and expand our relationship with MGH to provide expert teams in any medical subspecialty to meet the unique needs of your clinical trial.
I encourage you to visit often as we continue to add new services designed to meet your clinical imaging needs, no matter how complex.
Sincerely,
Dr. Richard Walovitch
President
WorldCare Clinical, L.L.C.
Dr. Walovitch joined WCC in January 2009 as chief medical officer. As president of WCC, Dr. Walovitch provides medical leadership for the entire organization. Additionally, he is responsible for directing the operations, regulatory, sales, and marketing activities and plays a vital role in defining the strategic vision of the company.
Prior to joining WCC, he served as the senior vice president of clinical research at Acusphere, Inc., vice president of preclinical and clinical research at Epix Medical, and held various positions as research pharmacologist and project clinician in the Imaging Agent Group at the DuPont Merck Pharmaceutical Company. He completed his postdoctoral fellowship at the National Institute on Drug Abuse’s Addiction Research Center in the Neurochemistry section. Walovitch has a doctorate in pharmacology from the University of Illinois Medical Center and a bachelor’s degree in biology from the University of Illinois. He is an author of more than 100 peer-reviewed publications, mostly in the field of medical imaging.
